HOME > Welcome message

Message from the President

Dear colleagues,


It is my great pleasure to announce the 22nd JSGCT Annual Meeting being held   on July 28 to July 30, 2016 at the Toranomon Hills Forum, Tokyo, Japan.  
The field of gene therapy has experienced a long time of slow progression until recently the news of “Glybera” being approved by regulatory authorities in the Western world to be the first medication for patients with Lipoprotein Lipase Deficiency. Along with other reports of gene therapy making highly meaningful effects on diseases such as adrenoleukodystrophy, metachromatic leukodystrophy, Wiskott-Aldrich Syndrome and adenosine deaminase (ADA) deficiency, these matters represent major breakthroughs and I, as a specialist in genetic diseases for many years, have no choice but to think that this field has definitely come to an important turning point to move out of this stagnation. Significant results achieved in domestic clinical research and clinical trials also may have made an influence on the cumulative total number of more than 500 participants at the 21st Annual Meeting held in Osaka this July.

Additionally to the above, the 22nd JSGCT Annual Meeting will be built upon the theme of “Gene Therapy: Heading toward Standard Therapy”, designated to bring into focus that gene therapy being a standard therapy for intractable and rare diseases, and also it will be the first meeting after the renewal of the society’s name to “Japan Society of Gene and Cell Therapy” in order to expand our collaborations with other international societies.

At this Meeting, we are planning Main Symposium, 6 Scientific Symposiums, Asian Session and Technical Seminars, and privileged to have many distinguished researchers such as Dr. Cynthia E. Dunbar (NIH, President-Elect of ASGCT), Dr. Alessandra Biffi of The San Raffaele Telethon Institute for Gene Therapy (TIGET) and more.

I truly hope that the 22nd JSGCT Annual Meeting will be stimulating and enjoyable for all participants and look forward to welcoming many of you at Toranomon Hills Forum, Tokyo 2016.

Sincerely yours,

Toya Ohashi M.D., Ph.D.
President of the 22nd JSGCT 2016
Director, Research Center for Medical Sciences
Professor, Department of Pediatrics
The Jikei University School of Medicine

JSGCT:Japan Society 
of Gene and Cell Therapy

Secretariat Office

Division of Gene Therapy,
Research Center for Medical Sciences
Department of Pediatrics
The Jikei University School of Medicine

3−25−8 Nishi-Shinbashi, Minato-ku,
Tokyo 105-8461, Japan
E-mail: jsgct2016@jsgt.jp
Fax: +81-3-3433-1230

Inquiry:

E-mail: jsgct2016@jsgt.jp
Fax: +81-43-306-5664
JSGCT Administrative Office

Back to Top